Affiliation:
1. National Medical Research Center of Phthisiopulmonology and Infectious Diseases, Russian Ministry of Health
2. National Medical Research Center of Phthisiopulmonology and Infectious Diseases, Russian Ministry of Health; Pirogov Russian National Research Medical University, Russian Ministry of Health
Abstract
The objective: based on a systematic review and meta-analysis of data from published results of clinical studies, to evaluate clinical efficacy and safety of chemotherapy regimens containing clofazimine in MDR-TB patients.Subjects and Methods. A systematic analysis of publications was performed using key words “clofazimine”, “tuberculosis treatment”, “mycobacteria drug resistance”, and “safety” in electronic libraries: PubMed, Google Scholar, eLIBRARY.RU, and medRvix. 7 clinical studies were selected for further analysis.Results. The risk of treatment failure in main groups receiving regimens containing clofazimine was 1.7 times lower versus control groups (without clofazimine) (p = 0.02; RR = 0.6 (95% CI: 0.39 – 0.92)). The risk of sputum conversion by week 12 of treatment is 7 times higher in main groups receiving regimens containing clofazimine versus control groups (p = 0.01; RR = 0.14 (95% CI: 0.03 – 0.25)). The risk of adverse events in main groups receiving regimens containing clofazimine was comparable to control groups (p = 0.54; RR = 1.27 (95% CI: 0.59 – 2.71)).
Publisher
LLC "Medical Knowledge and Technologies"
Reference22 articles.
1. Gayda A.I., Sveshnikova O.M., Verkhovaya V.N., Makhmaeva S.V., Nikishova E.I., Maryandyshev A.O. Treatment of tuberculosis patients with extensive drug resistance using new anti-tuberculosis drugs in the civilian community of Arkhangelsk Region. Tuberculosis and Lung Diseases, 2018, vol. 96, no. 7, pp. 5-10. (In Russ.)
2. Zhdanova E.V., Turdumambetova G.K. Short-course chemotherapy regimen of multidrug-resistant tuberculosis in the Kyrgyz Republic. Vestnik Avitsenny, 2018, no. 2-3. (In Russ.) Available: https://cyberleninka.ru/article/n/lechenie-tuberkulyoza-s-mnozhestvennoy-lekarstvennoy-ustoychivostyu-kratkosrochnymi-shemami-himioterapii-v-kyrgyzskoy-respublike Accessed March 24, 2023.
3. Maryandyshev A.O., Lorsanov S.M., Khaydarkhanova Z.B., Khunkarsultanov S.B., Perkhin D.V., Sveshnikova O.M., Gayda A.I., Privolnev V.V. Treatment outcomes of regimens containing delamanid within therapy of multiple and extensive drug resistant tuberculosis in the Russian Federation. Tuberculosis and Lung Diseases, 2019, vol. 97, no. 11, pp. 67-68. (In Russ.)
4. Mozhokina G.N., Samoylova A.G. Clofazimine: history and perspectives. Tuberculosis and Lung Diseases, 2021, vol. 99, no. 5, pp. 64-70. (In Russ.)
5. Nikolenko N.Yu., Kudlay D.A., Borisov S.E., Sannikova T.E., Doctorova N.P. Сlinical and economic evaluation of various etiotropic chemotherapy regimens in patients with respiratory tuberculosis with multidrug and extensively drug resistance. Farmakoekonomika, Modern Pharmacoeconomics and Pharmacoepidemiology, 2023, no. 16(2), pp. 162-175. (In Russ.) https://doi.org/10.17749/2070-4909/farmakoekonomika.2023.179.